{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:16:38Z","timestamp":1648829798483},"reference-count":0,"publisher":"Portland Press Ltd.","issue":"s4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1978,1,1]]},"abstract":"<jats:p>1. Noradrenaline content of several rat brain stem and hypothalamic nuclei falls transiently at 72 h after initiation of renovascular hypertension (one-kidney Goldblatt model).<\/jats:p>\n               <jats:p>2. Tyrosine hydroxylase activity is significantly reduced in posterior, paraventricular and periventricular nuclei of hypothalamus at this time but returns to control value by 7 days.<\/jats:p>\n               <jats:p>3. Treatment with hydrallazine, 5 mg\/kg intraperitoneally, twice daily or methoxamine, 5 mg\/kg, three times daily for 3 days respectively raises and lowers the noradrenaline content of brain nuclei, suggesting that short-term changes in noradrenaline may be secondary to afferent baroreceptor input.<\/jats:p>\n               <jats:p>4. At later times after the development of renovascular hypertension (7 and 28 days) activity of phenylethanolamine-N-methyl transferase is increased in the nucleus of the solitary tract and the locus coeruleus.<\/jats:p>\n               <jats:p>5. Brain catecholamines may participate both early in the development and later in the maintenance of renovascular hypertension.<\/jats:p>","DOI":"10.1042\/cs055101s","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T10:34:59Z","timestamp":1438943699000},"page":"101s-103s","update-policy":"http:\/\/dx.doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain Catecholamines and Catecholamine-Synthesizing Enzymes in Renovascular Hypertension in the Rat"],"prefix":"10.1042","volume":"55","author":[{"given":"Margaret A.","family":"Petty","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Royal Postgraduate Medical School, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Royal Postgraduate Medical School, London"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/clinsci\/article-pdf\/55\/s4\/101s\/740710\/cs055101s.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/clinsci\/article-pdf\/55\/s4\/101s\/740710\/cs055101s.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T21:44:16Z","timestamp":1572126256000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/55\/s4\/101s\/101499\/Brain-Catecholamines-and-CatecholamineSynthesizing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1978,1,1]]},"references-count":0,"journal-issue":{"issue":"s4","published-print":{"date-parts":[[1978,1,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs055101s","relation":{},"ISSN":["0144-4107"],"issn-type":[{"value":"0144-4107","type":"print"}],"subject":[],"published":{"date-parts":[[1978,1,1]]}}}